Patents by Inventor Jerome Moreaux
Jerome Moreaux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230220480Abstract: The invention relates to the use of an iron-score based on the expression level of at least 2 genes, in particular at least 5, preferably at least 10, and even preferably 11 genes selected in the group consisting of ALAS1, HIF1A, LRP2, HMOX1, HMOX2, HFE, ISCA1, SLC25A37, PPOX, STEAP1 and TMPRSS6 involved in the iron metabolism, as a prognosis marker in subjects having DLBCL, in particular for identifying subjects with a poor outcome such as a relapse and/or death.Type: ApplicationFiled: November 6, 2020Publication date: July 13, 2023Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Jérôme MOREAUX, Raphaël RODRIGUEZ, Julie DEVIN, Caroline BRET, Tatiana CANEQUE COBO
-
Publication number: 20230175068Abstract: A method for in vitro prognosis of the outcome of an individual afflicted by an acute myeloid leukaemia. The method includes the following steps: (a) measuring the expression level of genes involved in 5 DNA repair pathways, (b) calculating a score value for each DNA repair pathway group of genes, and (c) classifying the individual as having a good or a bad outcome.Type: ApplicationFiled: April 14, 2021Publication date: June 8, 2023Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITÉ DE MONTPELLIERInventors: Jérôme MOREAUX, Ludovic GABELLIER, Caroline BRET
-
Patent number: 11578369Abstract: A method for in vitro predicting of the outcome of an individual having a multiple myeloma, including the steps of: a) measuring the expression level of at least 5 genes and/or proteins encoded by the 5 genes, the genes being selected in a group including NRP2, REEP1, SV2B, ARRB1, CACNA1G, FBLIM1, FGFR1, IRF6, ITGA9, NOVA2, PPP2R2C, SLC5A1, SORL1, SYT7 and THY1, in a biological sample obtained from the individual; b) calculating a score value from the expression level obtained at step a); c) classifying the individual as having a good prognosis status or a bad prognosis status, by comparing the score value obtained at step b) with a reference score value.Type: GrantFiled: October 31, 2017Date of Patent: February 14, 2023Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIERInventors: Jérôme Moreaux, Laurie Herviou, Alboukadel Kassambara, Giacomo Cavalli
-
Publication number: 20220396840Abstract: The invention relates to the use of an iron-score based on the expression level of at least 1 gene, in particular at least 3, preferably at least 5, and even preferably 8 genes selected in the group consisting of APEX1, TFRC, HIF1A, ABCG2, SCARA3, IREB2, SFXN4 and SLC39A14 involved in the iron metabolism, as a prognosis marker in subjects having MCL, in particular for identifying subjects with a poor outcome such as a relapse and/or death.Type: ApplicationFiled: November 6, 2020Publication date: December 15, 2022Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Jérôme MOREAUX, Raphaël RODRIGUEZ, Julie DEVIN, Caroline BRET, Tatiana CANEQUE COBO
-
Patent number: 11499197Abstract: The invention relates to a method for in vitro predicting the outcome of an individual having a multiple myeloma, comprising the steps of: a. measuring the expression level of genes coding for kinases, b. calculating a score value for each genes; and c. classifying the individual as having a good or a bad outcome.Type: GrantFiled: October 30, 2018Date of Patent: November 15, 2022Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITÉ DE MONTPELLIERInventors: Jerome Moreaux, Hugues De Boussac, Alboukadel Kassambara
-
Publication number: 20200399709Abstract: Disclosed is a method for in vitro predicting the outcome of an individual having a multiple myeloma, including: -a) measuring the expression level of at least 2 genes encoding a ROS detoxifying (AOX) protein selected in a group including AKR1 B1, ARNT, CAT, CBR DHCR24, EGLN1, GLRX2, HIF1A, MGST1, MSRB1, PRDX6, SLC7A1 1, SOD1, SRXN1, TALDO1 and TXN and/or the expression level of at least 2 genes encoding ROS producing (ROS) protein selected in a group including CYBA, CYB5A, CYC1, NCF1 B, NCF1 C, NCF4, NDUFA12, NDUFS2, NDUFS8, SHC1 and UQCR10, in a biological sample obtained from the individual; -b) calculating an AOX score value and/or a ROS score value from the respective expression level(s) obtained at step a); -c) classifying the individual as having a good prognosis status or a bad prognosis status, by comparing the score value obtained at step b) with a reference score value.Type: ApplicationFiled: February 7, 2019Publication date: December 24, 2020Inventors: Alboukadel KASSAMBARA, Jérôme MOREAUX, Wafa HASSEN
-
Publication number: 20200330467Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of multiple myeloma. In particular, the present invention relates to a method of treating multiple myeloma in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a SETD8 inhibitor.Type: ApplicationFiled: February 15, 2017Publication date: October 22, 2020Inventors: Jérôme MOREAUX, Eric JULIEN, Fanny IZARD, Charlotte GRIMAUD, Laurie HERIOU
-
Publication number: 20200325542Abstract: The invention relates to a method for in vitro predicting the outcome of an individual having a multiple myeloma, comprising the steps of: a. measuring the expression level of genes coding for kinases, b. calculating a score value for each genes; and c. classifying the individual as having a good or a bad outcome.Type: ApplicationFiled: October 30, 2018Publication date: October 15, 2020Inventors: Jerome MOREAUX, Hugues DE BOUSSAC, Alboukadel KASSAMBARA
-
Patent number: 10676791Abstract: The present invention relates to a method of testing whether a patient suffering from arge B-cell lymphoma will respond or not to a DNA repair pathway inhibitor comprising: i) determining the expression level (ELi) of several genes Gi-Gn selected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the DNA repair score trough the following formula (I), wherein ?i represent the regression ? coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=?1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score DNARS determined at step iii) with a predetermined reference value DNARSR v) and concluding that the patient will respond to the treatment when the DNARS score is higher than the predetermined reference value DNARSg oType: GrantFiled: July 27, 2015Date of Patent: June 9, 2020Assignees: INSERM(INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Jerome Moreaux, Guillaume Cartron, Caroline Bret, Angelos Constantinou, Philippe Pasero
-
Patent number: 10662481Abstract: The present invention relates to a method of testing whether a patient suffering from multiple myeloma will respond or not to a combination treatment consisting of at least one histone deacetylase inhibitor (HDACi) with at least one DNA methyltransferase inhibitors (DNMTi) comprising: i) determining the expression level (ELi) of several genes G1-Gn selected from table A in a biological sample obtained from said patient ii) comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HADMS score trough the following formula (I) wherein ?i represent the regression ? coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=?1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score HADMS determined at step iii) with a predetermined reference value HADMSR v) and concluding that the patieType: GrantFiled: March 20, 2015Date of Patent: May 26, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIERInventors: Jérôme Moreaux, Bernard Klein
-
Publication number: 20200063209Abstract: A method for in vitro predicting of the outcome of an individual having a multiple myeloma, including the steps of: a) measuring the expression level of at least 5 genes and/or proteins encoded by the 5 genes, the genes being selected in a group including NRP2, REEP1, SV2B, ARRB1, CACNA1G, FBLIM1, FGFR1, IRF6, ITGA9, NOVA2, PPP2R2C, SLC5A1, SORL1, SYT7 and THY1, in a biological sample obtained from the individual; b) calculating a score value from the expression level obtained at step a); c) classifying the individual as having a good prognosis status or a bad prognosis status, by comparing the score value obtained at step b) with a reference score value.Type: ApplicationFiled: October 31, 2017Publication date: February 27, 2020Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIERInventors: Jérôme MOREAUX, Laurie HERVIOU, Alboukadel KASSAMBARA, Giacomo CAVALLI
-
Publication number: 20200041513Abstract: The invention relates to a method for detecting, by means of flow cytometry, the presence of normal plasma cells and tumoral plasma cells in a sample of cells from a patient.Type: ApplicationFiled: May 22, 2017Publication date: February 6, 2020Inventors: Guilhem REQUIRAND, Bernard KLEIN, Thierry REME, Jérôme MOREAUX, Sébastien RAIMBAULT, Philippe NERIN, Rosalie PLANTEFEVE, Elina ALATERRE, Jean-Michel GARCIA
-
Publication number: 20190234950Abstract: Disclosed is the use of an expression level value of each of the four markers selected in a group consisting of CD24, CD27, CD36 and CD302 in a sample obtained from an individual affected with a multiple myeloma for predicting an outcome of a multiple myeloma in the individual.Type: ApplicationFiled: June 2, 2017Publication date: August 1, 2019Inventors: Elina ALATERRE, Jérôme MOREAUX
-
Patent number: 10174380Abstract: The present invention relates to a method of testing whether a patient suffering of myeloma will respond or not to a histone deacetylase inhibitor (HDACi) comprising: determining the expression level (ELi) of several genes G1-Gn selected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HAS score trough the following formula wherein ?i represent the regression ? coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=?1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) comparing the score HAS determined at step iii) with a predetermined reference value HASR v) and concluding that the patient will respond to the HDACi when the HAS score is higher than the predetermined reference value HASR or concluding that the patient will noType: GrantFiled: October 8, 2013Date of Patent: January 8, 2019Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Montpellier, Centre Hospitalier Universitaire de MontpellierInventors: Jerome Moreaux, Bernard Klein
-
Publication number: 20170211151Abstract: The present invention relates to a method of testing whether a patient suffering from arge B-cell lymphoma will respond or not to a DNA repair pathway inhibitor comprising: i) determining the expression level (ELi) of several genes Gi-Gn selected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the DNA repair score trough the following formula (I), wherein ?i represent the regression ? coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=?1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score DNARS determined at step iii) with a predetermined reference value DNARSR v) and concluding that the patient will respond to the treatment when the DNARS score is higher than the predetermined reference value DNARSg oType: ApplicationFiled: July 27, 2015Publication date: July 27, 2017Inventors: Jérôme MOREAUX, Guillaume CARTRON, Caroline BRET, Angelos CONSTANTINOU, Philippe PASERO
-
Publication number: 20170096710Abstract: The present invention relates to a method of testing whether a patient suffering from multiple myeloma will respond or not to a combination treatment consisting of at least one histone deacetylase inhibitor (HDACi) with at least one DNA methyltransferase inhibitors (DNMTi) comprising: i) determining the expression level (ELi) of several genes G1-Gn selected from table A in a biological sample obtained from said patient ii) comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HADMS score trough the following formula (I) wherein ?i represent the regression ? coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=?1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score HADMS determined at step iii) with a predetermined reference value HADMSR v) and concluding that the patieType: ApplicationFiled: March 20, 2015Publication date: April 6, 2017Inventors: Jérôme MOREAUX, Bernard KLEIN
-
Publication number: 20150275305Abstract: The present invention relates to a method of testing whether a patient suffering of myeloma will respond or not to a histone deacetylase inhibitor (HDACi) comprising: determining the expression level (ELi) of several genes G1-Gn selected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HAS score trough the following formula wherein ?i represent the regression ? coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=?1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) comparing the score HAS determined at step iii) with a predetermined reference value HASR v) and concluding that the patient will respond to the HDACi when the HAS score is higher than the predetermined reference value HASR or concluding that the patient will noType: ApplicationFiled: October 8, 2013Publication date: October 1, 2015Inventors: Jérôme Moreaux, Bernard Klein
-
Publication number: 20150218654Abstract: The present invention relates to a method of testing whether a patient suffering of multiple myeloma will respond or not to a DNA methyltransferase inhibitor (DNMTi) comprising: i. determining the expression level (ELi) of several genes G1-Gn selected from table A in a biological sample obtained from said patient ii. comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii.Type: ApplicationFiled: September 23, 2013Publication date: August 6, 2015Inventors: Jerome Moreaux, Bernard Klein